

Review

***Corresponding author**
Maristella Adami, PhD
Department of Neuroscience
University of Parma
Via Volturmo 39
43125 Parma Italy
Tel. +39 0521 903943
Fax: +39 0521 903852
E-mail: maristella.adami@unipr.it

Volume 1 : Issue 1

Article Ref. #: 1000GOJ1103

Article History

Received: May 30th, 2014

Accepted: June 12th, 2014

Published: July 16th, 2014

Citation

Adami M, Coruzzi G. The Histamine H₄ Receptor: a novel target for safe anti-inflammatory drugs?. *Gastro Open J.* 2014; 1(1): 7-12. doi: [10.17140/GOJ-1-103](https://doi.org/10.17140/GOJ-1-103)

Copyright

©2014 Adami M. This is an open access article distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The Histamine H₄ Receptor: A Novel Target for Safe Anti-inflammatory Drugs?

Maristella Adami* and Gabriella Coruzzi¹

Department of Neuroscience, University of Parma, Via Volturmo 39, 43125 Parma, Italy

¹retired

ABSTRACT

The functional role of histamine H₄ receptors (H₄Rs) in the Gastrointestinal (GI) tract is reviewed, with particular reference to their involvement in the regulation of gastric mucosal defense and inflammation. H₄Rs have been detected in different cell types of the gut, including immune cells, paracrine cells, endocrine cells and neurons, from different animal species and humans; moreover, H₄R expression was reported to be altered in some pathological conditions, such as colitis and cancer. Functional studies have demonstrated protective effects of H₄R antagonists in several experimental models of gastric mucosal damage and intestinal inflammation, suggesting a potential therapeutic role of drugs targeting this new receptor subtype in GI disorders, such as allergic enteropathy, Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS) and cancer.

KEYWORDS: Histamine H₄ receptor; Stomach; Intestine.

ABBREVIATIONS: CNS: Central Nervous System; GI: Gastrointestinal; H₃Rs: H₃ Receptors; H₄Rs: H₄ Receptors; IBD: Inflammatory Bowel Disease; IBS: Irritable Bowel Syndrome; IL-6: Interleukin-6; NSAIDs: Nonsteroidal Anti-inflammatory Drugs; TNBS: Trinitrobenzene Sulphonic Acid; TNF- α : Tumour Necrosis Factor-alpha; UC: Ulcerative Colitis.

INTRODUCTION

After the discovery of histamine H₂ receptors and their revolutionary role in the therapy of gastroduodenal ulcer,¹⁻³ the research on Gastrointestinal (GI) histamine was considered to be settled. However, renewed interest in the amine emerged in the '90s with the discovery of the histamine H₃ receptor (H₃R),^{4,5} and subsequently, in the early 2000 when the H₄ receptor (H₄R) was detected from the human genome database by several independent groups.⁶⁻⁸ As a consequence, novel therapeutic fields have been unravelled for antihistamine drugs: whereas histamine H₃R antagonists may represent new therapeutic options for cognitive, sleep and memory disorders^{5,9} and for obesity,¹⁰ H₄R antagonists are currently the object of intensive research, as potential candidates in the therapy of allergy, inflammatory disorders, neurophatic pain and pruritus.^{7,11,12}

The present review will focus on the location and functional role of H₄Rs in the GI tract and the potential clinical implications for human diseases. Beneficial effects of H₄R blockers at GI level would be of particular interest, when considering that the available Nonsteroidal Anti-inflammatory Drugs (NSAIDs) are still endowed with significant gastric and intestinal toxicity.¹³⁻¹⁴ This is particularly true for the still unrecognized NSAID-induced enteropathy, which occurs frequently and still awaits for medical treatment.¹⁵⁻¹⁶

THE HISTAMINE H₄R

The H₄R is a G-protein coupled receptor which has been primarily detected outside the Central Nervous System (CNS), and, in particular, in immune and inflammatory cells, including mast cells, eosinophils, basophils, dendritic cells and T cells.⁶⁻⁸ This has led to hypothesize for the H₄R a key role in inflammation and immunoregulation. Indeed, a variety of *in vitro* data have shown that H₄Rs are involved in the control of chemotactic response and cytoskeletal changes of human eosinophils, mast cell chemotaxis and release of interleukin-16 from human CD8⁺ T cells and dendritic cell migration.^{7-8,17} Functional *in vivo* studies in rodents have confirmed anti-inflammatory, antihyperalgesic and antiallergic effects of selective H₄R antagonists in a variety of acute and chronic experimental models.¹⁸⁻²⁴

HISTAMINE H₄R LIGANDS

Since H₃R and H₄R are closely related, the early pharmacological characterization of the H₄R was based on compounds retaining the ability to bind the H₃R subtype.²⁵ The first selective H₄R antagonist was the indolylpiperazine compound, JNJ7777120, which displayed high affinity (K_i = 4 nM) for the human H₄R with and a >1000-fold selectivity over the other histamine receptors,²⁶ thus becoming the “reference” H₄R ligand in most experimental assays, also due to the lack of highly selective H₄R agonists.^{27,28} To complicate matters, the subsequent availability of chemically different H₄R ligands showed that several compounds could display a protean activity, behaving as full agonists, partial agonists or actually neutral antagonists, depending on the functional assay.²⁹⁻³² Indeed, some pharmacological discrepancies have recently emerged: H₄R activation, rather than blockade, was found to display anti-inflammatory or protective effects,^{30,32} and on the other hand, the “standard” H₄R antagonist JNJ7777120 was found to behave as an agonist in some experimental assays.^{29,31} The use of non selective compounds (i.e. mixed H₃/H₄ receptor ligands) and the occurrence of strain-dependent effects of H₄R ligands³³ may further contribute to an erroneous interpretation of experimental data and make the characterization of H₄R function a great challenge for histaminologists. Human studies are therefore highly recommended. Unfortunately, so far, only few compounds have entered into clinical trials: JNJ-39758979 in phase II for itch and asthma, ZPL-38937887 (PalauPharma) in phase I, UR-63325 (PalauPharma) in phase I with excellent safety and profile.³⁴

LOCATION OF H₄RS IN THE GI TRACT

H₄R expression was found throughout the GI tract of different animal species and humans.³⁵ As shown in Table 1, the expression was unraveled both in normal tissues and under pathological conditions, such as esophagitis and colitis;³⁶⁻⁴⁹ a decrease in H₄R density was reported in human gastric and colorectal carcinoma.^{39,55-56} Cell types expressing H₄R include immune and inflammatory cells, epithelial cells and neurons of the myenteric and submucous plexus. Interestingly, H₄R expression was found in ghrelin-producing cells of the rat stomach,³⁷ leading to

speculation about a possible role of histamine in the secretion of the orexigenic peptide.

Tissue	Normal/Pathological	Species	Ref.
Oesophagus	eosinophilic esophagitis	guinea pig	36
Stomach	normal	rat	37
	normal	human	38, 39
	carcinoma	human	39
Small intestine	normal	mouse	40
	normal	rat	41
	normal	dog	42
	normal	human	38,43-47
Colon	spontaneous colitis	mouse	48
	TNBS colitis	mouse	49
	normal	rat	41
	normal	dog	50
	normal	pig	51
	normal	monkey	52,53
	normal	human	44,47,54,55
	carcinoma	human	54-56
Rectum	carcinoma	human	54-56

H₄R= H₄ receptor; GI= Gastrointestinal; TNBS= Trinitrobenzene Sulphonic Acid

Table 1: Expression of histamine H₄Rs in the GI tract

GI EFFECTS OF H₄R LIGANDS

The functional data reported in intact animals with the available H₄R antagonists are summarized in Table 2.³⁵

Pathological condition	Species	Ref.
Indomethacin-induced gastric damage	rat, mouse	57,58
TNBS-induced colitis	rat	59-61
Zymosan-induced peritonitis	mouse	19,21,24,62-64
Radiation-induced intestinal damage	rat	65
Ischemia-induced intestinal damage	rat	66
TNBS-induced visceral hypersensitivity	rat	67

H₄R= H₄ receptor; GI= Gastrointestinal; TNBS= Trinitrobenzene Sulphonic Acid

Table 2: Protective effects of histamine H₄R antagonists in the GI tract

In rodents the reference H₄R antagonist JNJ7777120 was unable to damage the gastric mucosa per se, even at the highest anti-inflammatory doses and, actually, it was able to reduce the gastric damage induced by indomethacin^{57,58} in two models which are widely used to unravel either gastric damage or protection.¹³ The gastroprotection induced by H₄R blockade was unrelated to antisecretory effects or alteration in GI motility;³⁵ moreover, it was found to differ from that induced by activation of H₃Rs, since it was not evidenced against necrotizing agents, such as concentrated acid.⁶⁸ Indeed, the extensive damage induced by concentrated acid (>0.35 N) is only prevented by “true” cytoprotective drugs,

like prostaglandins¹⁴ or by mechanisms activating cellular defense, such as re-epithelization and cell proliferation.⁶⁹ It is thus more plausible to hypothesize a selective interference of H₄R antagonists in the widely recognized mechanism underlying NSAID-induced gastric damage, i.e. accumulation and activation of neutrophils in the gastric microvasculature.⁷⁰ In line with this, in several experimental models of intestinal damage, H₄R antagonists were able to reduce neutrophil infiltration in intestinal mucosa.^{19,21,24,62-64}

The gastric safety of H₄R antagonists could be of major interest, when considering that the available anti-inflammatory drugs are still endowed with gastric toxicity;¹⁴ nevertheless, the precise role of H₄R in the gastric mucosa remains to be proven, since data with selective ligands are intriguing: the H₄R agonist VUF8430²⁸ was paradoxically as effective as the antagonist JNJ7777120 in reducing indomethacin-induced lesions in the rat.⁵⁷

The protective effect reported by Varga et al.⁵⁹ in a model of acute colitis induced by Trinitrobenzene Sulphonic Acid (TNBS) seems deemed of interest, when considering that this model resembles the human Crohn's disease under macroscopic, histopathological and immunological aspects.⁷¹ In this assay, JNJ7777120 was able to reduce macroscopic damage, neutrophil infiltration and the production of both Tumor Necrosis Factor-alpha (TNF- α) and Interleukin-6 (IL-6), two cytokines that play a critical role in the pathogenesis of human disease.⁵⁹⁻⁶⁰ Several groups have underlined the increase in histamine content in mucosal biopsies from Crohn's disease, Ulcerative Colitis (UC) and food allergy;⁷²⁻⁷³ moreover, mast cells in colonic mucosal biopsies from IBS patients were found to release more histamine than in normal subjects.⁷³ The recent observation that histamine H₄Rs, together with H₁Rs, contribute to the postinflammatory visceral sensitivity in the TNBS-induced colitis assay,⁶⁷ leads to hypothesize that H₄R antagonists may be of therapeutic value in various pathological conditions with abdominal pain.

Finally, a possible role of histamine H₄Rs in cancer has been recently reviewed.⁷⁴ Recent studies have evidenced the presence of H₄Rs in gastric and colorectal tumor cells and a reduction of H₄R density has been observed, which parallels the cancer progression.^{54,55,56} However, functional data with histamine and H₄R ligands are contradictory, with both stimulation and/or inhibition of cell proliferation and cell growth being observed.⁷⁴

CONCLUSIONS

The protective effects displayed by some H₄R antagonists in a variety of experimental *in vivo* models suggest that histamine H₄R blockade is not deleterious for the GI tract and can actually activate gastric and intestinal mucosal defense mechanisms, at least in rodents. Despite these favourable premises, H₄R pharmacology is still intriguing and

clinical studies are mandatory in order to assess the potential benefit of H₄R antagonists in human GI disease. A careful validation of experimental assays, ligand selectivity and antibody specificity is of key importance to unravel the location and functional role of H₄Rs in the GI tract, and the therapeutic value of drugs targeting this receptor in the human pathology.

ACKNOWLEDGEMENTS

The work is part of the EU FP7 COST Action BM0806: Recent advances in histamine receptor H₄R research.

REFERENCES

1. Black JW, Duncan WA, Durant CJ, Ganellin CR, Parsons EM. Definition and antagonism of histamine H₂-receptors. *Nature*. 1972; 236: 385-390. doi: [10.1038/236385a0](https://doi.org/10.1038/236385a0)
2. Feldman M, Burton ME. Histamine₂-receptor antagonists. Standard therapy for acid-peptic diseases. First part. *N Engl J Med*. 1990; 323: 1672-1680. doi: [10.1056/NEJM199012133232405](https://doi.org/10.1056/NEJM199012133232405)
3. Feldman M, Burton ME. Histamine₂-receptor antagonists. Standard therapy for acid-peptic diseases. Second part. *N Engl J Med*. 1990; 323: 1749-1755. doi: [10.1056/NEJM199012203232507](https://doi.org/10.1056/NEJM199012203232507)
4. Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H₃) of histamine receptors. *Nature*. 1983; 302: 832-837. doi: [10.1038/302832a0](https://doi.org/10.1038/302832a0)
5. Vohora D. The third Histamine Receptor: Selective Ligands as Potential Therapeutic Agents in CNS Disorders. Boca Raton, FL (USA); CRC Press, *Taylor and Francis Group*; 2008.
6. Leurs R, Chazot PL, Shenton FC, Lim HD, de Esch IJ. Molecular and biochemical pharmacology of the histamine H₄ receptor. *Br J Pharmacol*. 2009; 157: 14-23. doi: [10.1111/j.1476-5381.2009.00250.x](https://doi.org/10.1111/j.1476-5381.2009.00250.x)
7. Zampeli E, Tiligada E. The role of histamine H₄ receptor in immune and inflammatory disorders. *Br J Pharmacol*. 2009; 157: 24-33. doi: [10.1111/j.1476-5381.2009.00151.x](https://doi.org/10.1111/j.1476-5381.2009.00151.x)
8. Stark H. Histamine H₄ receptor: a novel target in immunoregulation and inflammation. London, Great Britain; *Versita Ltd*; 2013.
9. Celanire S, Wijtmans M, Talaga P, Leurs R, de Esch IJ. Key-note review: histamine H₃ receptor antagonists reach out for the clinic. *Drug Discov Today*. 2005; 10: 1613-1627. doi: [10.1016/S1359-6446\(05\)03625-1](https://doi.org/10.1016/S1359-6446(05)03625-1)
10. Passani MB, Blandina P, Torrealba F. The histamine H₃ receptor and eating behaviour. *J Pharmacol Exp Ther*. 2011; 336: 24-29. doi: [10.1124/jpet.110.171306](https://doi.org/10.1124/jpet.110.171306)

11. Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. *Nat Rev Drug Discov.* 2008; 7: 41-53. doi: [10.1038/nrd2465](https://doi.org/10.1038/nrd2465)
12. Engelhardt H, Smits RA, Leurs R, Haaksma E, de Esch IJ. A new generation of anti-histamines: Histamine H4 receptor antagonists on their way to the clinic. *Curr Opin Drug Discov Devel.* 2009; 12: 628-643.
13. Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? *Physiol Rev.* 2008; 88: 1547-1565. doi: [10.1152/physrev.00004.2008](https://doi.org/10.1152/physrev.00004.2008)
14. Wallace JL. COX-2: a pivotal enzyme in mucosal protection and resolution of inflammation. *Scientific World Journal.* 2006; 6: 577-588. doi: <http://dx.doi.org/10.1100/tsw.2006.122>
15. Whittle BJ. Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors. *Eur J Pharmacol.* 2004; 500: 427-439. doi: [10.1016/j.ejphar.2004.07.042](https://doi.org/10.1016/j.ejphar.2004.07.042)
16. Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. *World J Gastroenterol.* 2013; 19: 1861-1876. doi: [10.3748/wjg.v19.i12.1861](https://doi.org/10.3748/wjg.v19.i12.1861)
17. Zhang M, Thurmond RL, Dunford PJ. The histamine H4 receptor: a novel modulator of inflammatory and immune disorders. *Pharmacol Ther.* 2007; 113: 594-606. doi: [10.1016/j.pharmthera.2006.11.008](https://doi.org/10.1016/j.pharmthera.2006.11.008)
18. Strakhova MI, Cuff CA, Manelli AM, et al. In vitro and in vivo characterization of A-940894: a potent histamine H4 receptor antagonist with anti-inflammatory properties. *Br J Pharmacol.* 2009; 157: 44-54. doi: [10.1111/j.1476-5381.2009.00236.x](https://doi.org/10.1111/j.1476-5381.2009.00236.x)
19. Takeshita K, Sakai K, Bacon KB, Gantner F. Critical role of histamine H4 receptor in leukotriene B4 production and mast cell-dependent neutrophil recruitment induced by zymosan in vivo. *J Pharmacol Exp Ther.* 2003; 307: 1072-1078. doi: [10.1124/jpet.103.057489](https://doi.org/10.1124/jpet.103.057489)
20. Bell JK, McQueen DS, Rees JL. Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in Balb C mice. *Br J Pharmacol.* 2004; 142: 374-380. doi: [10.1038/sj.bjp.0705754](https://doi.org/10.1038/sj.bjp.0705754)
21. Thurmond RL, Desai PJ, Dunford PJ, et al. A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. *J Pharmacol Exp Ther.* 2004; 309: 404-413. doi: [10.1124/jpet.103.061754](https://doi.org/10.1124/jpet.103.061754)
22. Coruzzi G, Adami M, Guaita E, de Esch IJ, Leurs R. Anti-inflammatory and antinociceptive effects of the selective histamine H4-receptor antagonists JNJ7777120 and VUF6002 in a rat model of carrageenan-induced acute inflammation. *Eur J Pharmacol.* 2007; 563: 240-244. doi: [10.1016/j.ejphar.2007.02.026](https://doi.org/10.1016/j.ejphar.2007.02.026)
23. Ahmad SF, Zoheir KM, Abdel-Hamied HE, et al. The role of a histamine 4 receptor as an anti-inflammatory target in carrageenan-induced pleurisy in mice. *Immunology.* 2014; Jan 25. doi: [10.1111/imm.12257](https://doi.org/10.1111/imm.12257).
24. Hsieh GC, Chandran P, Salyers AK, et al. H4 receptor antagonism exhibits anti-nociceptive effects in inflammatory and neuropathic pain models in rats. *Pharmacol Biochem Behav.* 2010; 95: 41-50. doi: [10.1016/j.pbb.2009.12.004](https://doi.org/10.1016/j.pbb.2009.12.004)
25. de Esch IJ, Thurmond RL, Jongejan A, Leurs R. The histamine H4 receptor as a new therapeutic target for inflammation. *Trends Pharmacol Sci.* 2005; 26: 462-469. doi: <http://dx.doi.org/10.1016/j.tips.2005.07.002>
26. Jablonowski JA, Grice CA, Chai W, et al. The first potent and selective non-imidazole human histamine H4 receptor antagonists. *J Med Chem.* 2003; 46: 3957-3960. doi: [10.1021/jm0341047](https://doi.org/10.1021/jm0341047)
27. Lim HD, van Rijn RM, Ling P, Bakker RA, Thurmond RL, Leurs R. Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. *J Pharmacol Exp Ther.* 2005; 314: 1310-1321. doi: [10.1124/jpet.105.087965](https://doi.org/10.1124/jpet.105.087965)
28. Lim HD, Smits RA, Bakker RA, van Dam CM, de Esch IJ, Leurs R. Discovery of S-(2-guanidylethyl)-isothioureia (VUF 8430) as a potent nonimidazole H4 receptor agonist. *J Med Chem.* 2006; 49: 6650-6651. doi: [10.1021/jm060880d](https://doi.org/10.1021/jm060880d)
29. Rosethorne EM, Charlton SJ. Agonist-biased signaling at the histamine H4 receptor: JNJ7777120 recruits β -arrestin without activating G proteins. *Mol Pharmacol.* 2011; 79: 749-757. doi: [10.1124/mol.110.068395](https://doi.org/10.1124/mol.110.068395)
30. Seifert R, Schneider EH, Dove S, et al. Paradoxical stimulatory effects of the "standard" histamine H4-receptor antagonist JNJ7777120: the H4 receptor joins the club of 7 transmembrane domain receptors exhibiting functional selectivity. *Mol Pharmacol.* 2011; 79: 631-638. doi: [10.1124/mol.111.071266](https://doi.org/10.1124/mol.111.071266)
31. Neumann D, Beermann S, Seifert R. Does the histamine H4 receptor have a pro- or anti-inflammatory role in murine bronchial asthma? *Pharmacology.* 2010; 85: 217-223. doi: [10.1159/000285088](https://doi.org/10.1159/000285088)
32. Adachi N, Liu K, Motoki A, Nishibori M, Arai T. Suppression of ischemia/reperfusion liver injury by histamine H4 receptor stimulation in rats. *Eur J Pharmacol.* 2006; 544: 181-187. doi: [10.1016/j.ejphar.2006.06.053](https://doi.org/10.1016/j.ejphar.2006.06.053)

33. Coruzzi G, Pozzoli C, Adami M, et al. Strain-dependent effects of the histamine H4 receptor antagonist JNJ7777120 in a murine model of acute skin inflammation. *Exp Dermatol*. 2012; 21: 32-37. doi: [10.1111/j.1600-0625.2011.01396.x](https://doi.org/10.1111/j.1600-0625.2011.01396.x)
34. Schreab A, Lazewska D, Dove S, Buschauer A, Kiec-Kononowicz K, Stark H. Histamine H4 receptor ligands. In: Stark H, ed. Histamine H4 receptor: a novel drug target in immunoregulation and inflammation. London, Great Britain: Versita Ltd; 2013: 21-61.
35. Coruzzi G, Adami M, Pozzoli C. Role of histamine H4 receptors in the gastrointestinal tract. *Front Biosci*. 2012; 4: 226-239.
36. Yu S, Stahl E, Li Q, Ouyang A. Antigen inhalation induces mast cells and eosinophils infiltration in the guinea pig esophageal epithelium involving histamine-mediated pathway. *Life Sci*. 2008; 82: 324-330. doi: [10.1016/j.lfs.2007.12.002](https://doi.org/10.1016/j.lfs.2007.12.002)
37. Morini G, Becchi G, Shenton FC, Chazot PL, Grandi D. Histamine H3 and H4 receptors are expressed on distinct endocrine cell types in the rat fundic mucosa. *Inflamm Res*. 2008; 57(Suppl. 1): S57-S58. doi: [10.1007/s00011-007-0628-9](https://doi.org/10.1007/s00011-007-0628-9)
38. Liu C, Ma X, Jiang X, Wilson SJ, Hofstra CL, Blevitt J. Cloning and pharmacological characterization of a fourth histamine receptor (H4) expressed in bone marrow. *Mol Pharmacol*. 2001; 59: 420-426. doi: [10.1124/mol.59.3.420](https://doi.org/10.1124/mol.59.3.420)
39. Zhang C, Xiong Y, Li J, et al. Deletion and down-regulation of HRH4 gene in gastric carcinomas: a potential correlation with tumor progression. *PLoS One*. 2012; 7: e31207. doi: [10.1371/journal.pone.0031207](https://doi.org/10.1371/journal.pone.0031207)
40. Takagaki K, Osawa S, Horio Y, et al. Cytokine responses of intraepithelial lymphocytes are regulated by histamine H2 receptor. *J Gastroenterol*. 2009; 44: 285-296. doi: [10.1007/s00535-009-0019-9](https://doi.org/10.1007/s00535-009-0019-9)
41. Chazot PL, Shenton FC, Waldvogel H, Grandi D, Morini G. The H4 histamine receptor is expressed in both the human CNS and rodent PNS. In: European Histamine Research Society, 36th Annual Meeting, Florence (Italy), May 9-12th, 2007: 27.
42. Jiang W, Lim HD, Zhang M, et al. Cloning and pharmacological characterization of the dog histamine H4 receptor. *Eur J Pharmacol*. 2008; 592: 26-32. doi: [10.1016/j.ejphar.2008.06.095](https://doi.org/10.1016/j.ejphar.2008.06.095)
43. Nakamura T, Itadani H, Hidaka Y, Ohta M, Tanaka K. Molecular cloning and characterization of a new human histamine receptor, HH4R. *Biochem Biophys Res Commun*. 2000; 279: 615-620. doi: [10.1006/bbrc.2000.4008](https://doi.org/10.1006/bbrc.2000.4008)
44. Oda T, Morikawa N, Saito Y, Masuho Y, Matsumoto S. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. *J Biol Chem*. 2000; 275: 36781-36786. doi: [10.1074/jbc.M006480200](https://doi.org/10.1074/jbc.M006480200)
45. Cogè F, Guenin SP, Rique H, Boutin JA, Galizzi JP. Structure and expression of the human histamine H4-receptor gene. *Biochem Biophys Res Commun*. 2001; 284: 301-309. doi: [10.1006/bbrc.2001.4976](https://doi.org/10.1006/bbrc.2001.4976)
46. Morse KL, Behan J, Laz TM, et al. Cloning and characterization of a novel human histamine receptor. *J Pharmacol Exp Ther*. 2001; 296: 1058-1066.
47. Sander LE, Lorentz A, Sellge G, et al. Selective expression of histamine receptors H1R, H2R, and H4R, but not H3R, in the human intestinal tract. *Gut*. 2006; 55: 498-504.
48. Kumawat AK, Gotlind YY, Fredin MF, Willen R, Strid H, Hultgren-Hornquist E. Expression patterns of histamine receptors in the Gai2-deficient mouse model of colitis. *Inflamm Res*. 2010; 59(Suppl. 4): S358-S359.
49. Sutton TL, Zhao A, Madden KB, et al. Antiinflammatory mechanisms of enteric Heligmosomoides polygyrus infection against trinitrobenzene sulfonic acid-induced colitis in a murine model. *Infect Immun*. 2008; 76: 4772-4782. doi: [10.1128/IAI.00744-07](https://doi.org/10.1128/IAI.00744-07)
50. Eisenschenk MNC, Torres SM, Oliveira S, Been CS. The expression of histamine H4 receptor mRNA in the skin and other tissues of normal dogs. *Vet Dermatol*. 2011; 22: 396-400. doi: [10.1111/j.1365-3164.2011.00959.x](https://doi.org/10.1111/j.1365-3164.2011.00959.x)
51. Oda T, Matsumoto S, Masuho Y, et al. cDNA cloning and characterization of porcine histamine H4 receptor. *Biochim Biophys Acta*. 2002; 1575: 135-138. doi: [10.1016/S0167-4781-\(02\)00236-1](https://doi.org/10.1016/S0167-4781-(02)00236-1)
52. Oda T, Matsumoto S, Matsumoto M, et al. Molecular cloning of monkey histamine H4 receptor. *J Pharmacol Sci*. 2005; 98: 319-322. doi: [10.1254/jphs.SC0050033](https://doi.org/10.1254/jphs.SC0050033)
53. Kim H, Dwyer L, Song JH, et al. Identification of histamine receptors and effects of histamine on murine and simian colonic excitability. *Neurogastroenterol Motil*. 2011; 23: e949-e409. doi: [10.1254/jphs.SC0050033](https://doi.org/10.1254/jphs.SC0050033)
54. Cianchi F, Cortesini C, Schiavone NF, et al. The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer. *Clin Cancer Res*. 2005; 11: 6807-6815. doi: [10.1158/1078-0432.CCR-05-0675](https://doi.org/10.1158/1078-0432.CCR-05-0675)

55. Boer K, Helinger E, Helinger A, et al. Decreased expression of histamine H1 and H4 receptors suggests disturbance of local regulation in human colorectal tumours by histamine. *Eur J Cell Biol.* 2008; 87: 227-236. doi: [10.1016/j.ejcb.2007.12.003](https://doi.org/10.1016/j.ejcb.2007.12.003)
56. Fang Z, Yao W, Xiong Y, et al. Attenuated expression of HRH4 in colorectal carcinomas: a potential influence on tumor growth and progression. *BMC Cancer.* 2011; 11: 195-205. doi: [10.1186/1471-2407-11-195](https://doi.org/10.1186/1471-2407-11-195)
57. Coruzzi G, Adami M, Pozzoli C, Smits R, de Esch IJP, Leurs R. Gastroprotective effects of histamine H4 receptor ligands in rodent ulcer models. *Br J Pharmacol.* 2010; 7: 150P.
58. Adami M, Pozzoli C, Menozzi A, et al. Effects of histamine H4 receptor ligands in a mouse model of gastric ulceration. *Pharmacology.* 2012; 89: 287-294. doi: [10.1159/000337736](https://doi.org/10.1159/000337736)
59. Varga C, Horvath K, Berko A, Thurmond RL, Dunford PJ, Whittle BJ. Inhibitory effects of histamine H4 receptor antagonists on experimental colitis in the rat. *Eur J Pharmacol.* 2005; 522: 130-138. doi: [10.1016/j.ejphar.2005.08.045](https://doi.org/10.1016/j.ejphar.2005.08.045)
60. Dunford PJ, Varga C, Thurmond RL, Whittle BJ. Histamine H4 receptor antagonism attenuates toll-like receptor signaling and inhibits experimental colitis in the rat. *Gastroenterology.* 2006; 130: A-689.
61. Fogel WA, Jochem J, Lewinski A. Influence of the H3/H4 receptor antagonist, thioperamide on regional haemodynamics in rats with trinitrobenzene sulfonic acid-induced colitis. *Inflamm Res.* 2007; 56 (Suppl. 1): S21-S22. doi: [10.1007/s00011-006-0510-1](https://doi.org/10.1007/s00011-006-0510-1)
62. Cowart MD, Altenbach RJ, Liu H, et al. Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models. *J Med Chem.* 2008; 51: 6547-6557. doi: [10.1021/jm800670r](https://doi.org/10.1021/jm800670r)
63. Liu H, Altenbach RJ, Carr TL, et al. cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia. *J Med Chem.* 2008; 51: 7094-7098. doi: [10.1021/jm8007618](https://doi.org/10.1021/jm8007618)
64. Strakhova MI, Cuff CA, Manelli AM, et al. In vitro and in vivo characterization of A-940894: a potent histamine H4 receptor antagonist with anti-inflammatory properties. *Br J Pharmacol.* 2009; 157: 44-54. doi: [10.1111/j.1476-5381.2009.00236.x](https://doi.org/10.1111/j.1476-5381.2009.00236.x)
65. Medina V, Cricco G, Mohamad N, et al. Histamine is a selective protector against cellular damage produced by ionizing radiation. *Inflamm Res.* 2005; 54(Suppl. 1): S17-S18. doi: [10.1007/s00011-004-0407-9](https://doi.org/10.1007/s00011-004-0407-9)
66. Ghizzardi P, Gobetti T, Bertoni S, et al. Histamine H4 receptor antagonism and mesenteric ischemia/reperfusion injury in mice. *Gastroenterology.* 2009; 136 (Suppl. 1): A-397. doi: [http://dx.doi.org/10.1016/s0016-5085\(09\)61826-6](https://doi.org/http://dx.doi.org/10.1016/s0016-5085(09)61826-6)
67. Deiteren A, De Man JG, Ruysers NE, Moreels TG, Pelckmans PA, De Winter BY. Histamine H4 and H1 receptors contribute to postinflammatory visceral hypersensitivity. *Gut.* 2014; Feb 21. doi: [10.1136/gutjnl-2013-305870](https://doi.org/10.1136/gutjnl-2013-305870).
68. Coruzzi G, Adami M, Pozzoli C, de Esch IJ, Smits R, Leurs R. Selective histamine H3 and H4 receptor agonists exert opposite effects against the gastric lesions induced by HCl in the rat stomach. *Eur J Pharmacol.* 2011; 669: 121-127. doi: [10.1016/j.ejphar.2011.07.038](https://doi.org/10.1016/j.ejphar.2011.07.038)
69. Coruzzi G, Adami M. Peripheral actions and therapeutic potential in periphery. In: Vohora D, ed. *The third Histamine Receptor: Selective Ligands as Potential Therapeutic Agents in CNS Disorders.* New York, NY, USA: CRC Press, Taylor and Francis Group; 2008: 167-209.
70. Wallace JL, Keenan CM, Granger DN. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. *Am J Physiol.* 1990; 259: G462-G467.
71. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. *Gastroenterology.* 1995; 109: 1344-1367. doi: [http://dx.doi.org/10.1016/0016-5085\(95\)90599-5](https://doi.org/http://dx.doi.org/10.1016/0016-5085(95)90599-5)
72. Raithel M, Matek M, Baenkler HW, Jorde W, Hahn EG. Mucosal histamine content and histamine secretion in Crohn's disease, ulcerative colitis and allergy enteropathy. *Int Arch Allergy Immunol.* 1995; 108: 127-133.
73. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. *Gastroenterology.* 2004; 126: 693-702. doi: [http://dx.doi.org/10.1053/j.gastro.2003.11.055](https://doi.org/http://dx.doi.org/10.1053/j.gastro.2003.11.055)
74. Medina VA, Coruzzi G, Martinal Lamas DJ, et al. Histamine in cancer. In: Stark H ed. *Histamine H4 receptor: a novel drug target in immunoregulation and inflammation.* London, Great Britain, Versita Ltd. 2013; 259-308.